This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
by Kinjel Shah
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study
by Zacks Equity Research
Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
by Zacks Equity Research
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
by Kinjel Shah
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
AstraZeneca's Lynparza Gets China Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
by Zacks Equity Research
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
by Zacks Equity Research
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
by Zacks Equity Research
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
Seattle Genetics, Astellas Tie Up With Merck for Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
Why Is Merck (MRK) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Merck's (MRK) Shares Are Up This Year
by Zacks Equity Research
Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.
Esperion's Promising Drugs Under Review, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.